Diabetes-Induced alterations in platelet metabolism

Clinical Biochemistry

Volumn 30, Issue 7, 1997, Pages 509-515

  Mazzanti, Laura ^a   Mutus, Bulent ^b  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF WINDSOR   (Canada)

Author keywords

Ca2+ ATPase; Calmodulin; Complications; Diabetes mellitus; Glutathione; Glycation; Na+ K+ ATPase; Nitric oxide; Nitric oxide synthase; Oxidized LDL; Platelet

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); LOW DENSITY LIPOPROTEIN; NITRIC OXIDE SYNTHASE;

CALCIUM TRANSPORT; CELL MEMBRANE TRANSPORT; DIABETES MELLITUS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LIPID PEROXIDATION; POTASSIUM TRANSPORT; PRIORITY JOURNAL; REVIEW; SODIUM TRANSPORT; THROMBOCYTE MEMBRANE; THROMBOCYTE METABOLISM;

EID: 0030725190     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(97)00094-5     Document Type: Review

References (73)

1. Srivastava S, Joshi CS, Sethi PP, Agrawal AK, Srivastava SK, Seth PK. Altered platelet functions in non-insulin-dependent diabetes mellitus (NIDDM). Thromb Res. 76:1994;451-461.
2. Mandal S, Sarode R, Dash S, Dash RJ. Hyperaggregation of platelets detected by whole blood platelet aggregometry in newly diagnosed noninsulin-dependent diabetes mellitus. Am J Clin Pathol. 100:1993;103-107.
3. Bastyr EJ 3rd, Lu J, Stowe R, Green A, Vinik AI. Low molecular weight GTP-binding proteins are altered in platelet hyperaggregation in IDDM. Oncogene. 8:1993;515-518.
4. Bastyr EJ 3rd, Vinik AI. Reduced guanine nucleotide-stimulated polyphosphoinositide specific phospholipase C in platelet hyperaggregation in IDDM. Thromb Res. 65:1992;241-252.
5. Toth L, Szenasi P, Jambor G, Kammerer L, Romics L. Platelet function in male diabetics with and without macrovascular complications. Diabetes Res Clin Pract. 15:1992;143-148.
6. Rittenhouse SE. Human platelets contain phospholipase C that hydrolyzes polyphosphoinositides. Proc Natl Acad Sci USA. 80:1983;5417-5420.
7. Kaibuchi K, Takai Y, Sawamura M, Hoshijima M, Fujikura T, Nishizuka Y. Synergistic functions of protein phosphorylation and calcium mobilization in platelet activation. J Biol Chem. 258:1983;6701-6704.
8. Jones HP. Calmodulin and platelet function. Longnecker GL. The platelets physiology and pharmacology . 1985;221-235 Academic Press, New York.
9. Skou JC. The Na,K-pump. Met Enzymol. 156:1988;1-25.
10. Cornelius F. Functional reconstitution of sodium pump. Kinetics of exchange reactions performed by reconstituted Na/K-ATPase. Biochim Biophys Acta. 1071:1991;19-66.
11. 3H-ouabain binding to different types of human leucocytes. Br J Clin Pharmacol. 18:1984;153-158.
12. +-pump. J Cell Physiol. 151:1992;249-254.
13. Bork T, Mrsny RJ. Appearance of additional ouabain binding sites on platelet surfaces following activation. Exp Cell Res. 208:1993;189-196.
14. Blaunstein MP. Sodium ions, calcium ions, blood pressure regulation and hypertension a reassessment and a hypothesis . Am J Physiol. 232:1977;165-173.
15. Buhler FR, Resink TJ. Platelet abnormalities and the pathophysiology of essential hypertension. Experientia. 44:1988;94-97.
16. Enyedi A, Sarkadi B, Foldes-Papp Z, Monostory S, Gardos G. Demonstration of two distinct calcium pumps in human platelet membrane vesicles. J Biol Chem 1986; 261: 9558-9297.
17. 3H)-ouabain binding to different types of human leucocytes. Biochem J. 263:1989;547-552.
18. 2+)-ATPase from human platelets. Biochim Biophys Acta. 770:1984;159-165.
19. Nguyen BL, Saitoh M, Ware JA. Interaction of nitric oxide and cGMP with signal transduction in activated platelets. Am J Physiol. 261:1991;H1043-H1052.
20. Cornwell TL, Arnold E, Boerth NJ, Lincoln TM. Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP. Am J Physiol. 267:1994;C1405-C1413.
21. Lee SL, Wang WW, Fanburg BL. Nitroprusside inhibits serotonin-induced mitogenesis and tyrosine phosphorylation of smooth muscle cells. Am J Physiol. 270:1996;L362-L367.
22. Groves PH, Banning AP, Penny WJ, Newby AC, Cheadle HA, Lewis MJ. The effects of exogenous nitric oxide on smooth muscle cell proliferation following porcine carotid angioplasty. Cardiovasc Res. 30:1995;87-96.
23. Loscalzo J, Welch G. Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis. 38:1995;87-104.
24. 2+/calmodulin regulated nitric oxide synthases. Cell Calcium. 13:1992;427.
25. Venema RC, Sayegh HS, Arnal JF, Harrison DG. Role of the enzyme calmodulin-binding domain in membrane association and phospholipid inhibition of endothelial nitric oxide synthase. J Biol Chem. 270:1995;14705-14711.
26. Geller DA, Lowenstein CJ, Shapiro RA, et al. Molecular cloning and expression of inducible NOS from human hepatocytes. Proc Natl Acad Sci. 30:1993;3491-3495.
27. Baek KJ, Thiel BA, Lucas S, Stuehr DJ. Macrophage nitric oxide synthase subunits. Purification, characterization, and role of prosthetic groups and substrate in regulating their association into a dimeric enzyme. J Biol Chem. 268:1993;21120-21129.
28. Klatt P, Schmit K, Mayer B. Multiple catalytic functions of brain nitric oxide synthase. J Biol Chem. 268:1993;1478-14787.
29. 2+ concentration . Biochem Biophys Res Commun. 215:1995;842-848.
30. Muruganandam A, Mutus B. Isolation of nitric oxide synthase from human platelets. Biochim Biophys Acta. 1200:1994;1-6.
31. Chen LY, Mehta JL. Variable effects of L-arginine analogs on L-arginine-nitric oxide pathway in human neutrophils and platelets may relate to different nitric oxide synthase isoforms. J Pharmacol Exp Ther. 276:1996;253-257.
32. Chen LY, Mehta JL. Further evidence of the presence of constitutive and inducible nitric oxide synthase isoforms in human platelets. Cardiovasc Pharmacol. 27:1996;154-158.
33. de Belder A, Radomski M, Hancock V, Brown A, Moncada S, Martin J. Megakaryocytes from patients with coronary atherosclerosis express the inducible nitric oxide synthase. Arterioscler Thromb Vasc Biol. 15:1995;637-641.
34. Vasta V, Meacci E, Farnararo M, Bruni P. Identification of a specific transport system for L-arginine in human platelets. Biochem Biophys Res Commun. 206:1995;878-884.
35. Howard C, Sexton DJ, Mutus B. Evidence for regulation of human platelet L-Arg transport by S-nitrosothiols. Biochem Biophys Res Commun (submitted).
36. Nakatsuka M, Osawa Y. Selective inhibition of the 12-lipoxygenase pathway of arachidonic acid metabolism by L-arginine or sodium nitroprusside in intact human platelets. Biochem Biophys Res Commun. 200:1994;1630-1634.
37. Palinski W, Rosenfeld ME, Herttuala SY, et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA. 86:1989;1372-1376.
38. Moncada S, Higgs E, Palmer R. Nitric oxide physiology, pathophysiology and pharmacology . Pharmacol. Rev. 43:1991;109-142.
39. 2+-ATPase. Cell Calcium. 19:(5):1986;453-458.
40. Till U, Bosia A, Losche W, Spangenberg P, Pescarmona GP. Role of glutathione in platelet function. Folia Haematol Int Mag Klin Morphol Blutforsch. 115:1988;415-419.
41. Longenecker, GL Platelet arachidonic acid metabolism, In: The platelets: physiology and pharmacology. Pp. 159-185, Academic Press Inc. New York.
42. Aharony D, Smith JB, Silver MJ. Regulation of arachidonate-induced platelet aggregation by the lipoxygenase product, 12-hydroperoxyeicosatetraenoic acid. Biochim Biophys Acta. 718:1982;193-200.
43. Lands WE. Biological consequences of fatty acid oxygenase reaction mechanisms. Prostaglandins Leukot Med. 13:1984;35-46.
44. Burch JW, Burch PT. Glutathione disulfide production during arachidonic acid oxygenation in human platelets. Prostaglandins. 39:1990;123-134.
45. Simon DI, Stamler JS, Jaraki O, et al. Antiplatelet properties of protein S-nitrosothiols derived from nitric oxide and endothelium-derived relaxing factor. Arterioscler Thromb. 13:1993;791-799.
46. Marks DS, Vita JA, Folts JD, Keaney JF Jr, Welch GN, Loscalzo J. Inhibition of neointimal proliferation in rabbits after vascular injury by a single treatment with a protein adduct of nitric oxide. J Clin Invest. 96:1995;2630-2638.
47. Farkas J, Menzel EJ. Proteins lose their nitric oxide stabilizing function after advanced glycosylation. Biochim Biophys Acta. 1245:1995;305-310.
48. McDonald B, Reep B, Lapetina EG, Molina y Vedia L. Glyceraldehyde-3-phosphate dehydrogenase is required for the transport of nitric oxide in platelets. Proc Natl Acad Sci USA. 90:1993;11122-11126.
49. Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. J Biol Chem. 266:1991;4244-4250.
50. Ischiropoulos H, al-Mehdi AB. Peroxynitrite-mediated oxidative protein modifications. FEBS Lett. 364:1995;279-282.
51. van der Vliet A, Smith D, O'Neill CA, et al. Interactions of peroxynitrite with human plasma and its constituents oxidative damage and antioxidant depletion . Biochem J. 303:1994;295-301.
52. Beckman JS, Ischiropoulos H, Zhu L, et al. Kinetics of superoxide dismutase- and iron-catalyzed nitration of phenolics by peroxynitrite. Arch Biochem Biophys. 298:1992;438-445.
53. Francescutti D, Baldwin J, Lee L, Mutus B. Peroxynitrite modification of glutathione reductase modelling studies and kinetic evidence suggest the modification of tyrosines at the glutathione disulphide binding site . Protein Engineering. 9:1996;189-194.
54. Frears ER, Zhang Z, Blake DR, O'Connell JP, Winyard PG. Inactivation of tissue inhibitor of metalloproteinase-1 by peroxynitrite. FEBS Lett. 381:1996;21-24.
55. Moro MA, Darley-Usmar VM, Goodwin DA, et al. Paradoxical fate and biological action of peroxynitrite on human platelets. Proc Natl Acad Sci USA. 91:1994;6702-6706.
56. Thomas G, Lucas FV, Schumacher OP, Skrinska V. Behavior of intracellular glutathione during platelet thromboxane synthesis in diabetes. Prostaglandins Leukot Med. 22:1986;117-128.
57. Bosia A, Spangenberg P, Losche W, Arese P, Till U. The role of the GSH-disulfide status in the reversible and irreversible aggregation of human platelets. Thromb Res. 30:1983;137-142.
58. Muruganandam A, Drouillard C, Thibert RJ, Cheung RM, Draisey TF, Mutus B. Glutathione metabolic enzyme activities in diabetic platelets as a function of glycemic control. Thromb Res. 67:1992;385-397.
59. Muruganandam A, Tannous M, Mutus B. ELISA for in vivo assessment of nonenzymatically glycated platelet glutathione peroxidase. Clin Biochem. 27:1994;293-298.
60. Baldwin JS, Lee L, Leung TK, Muruganandam A, Mutus B. Identification of the site of non-enzymatic glycation of glutathione peroxidase rationalization of the glycation-related catalytic alterations on the basis of three-dimensional protein structure . Biochim Biophys Acta. 1247:1995;60-64.
61. Muruganandam A, Romsa GJ, Thibert RJ, Cheung RMC, Draisey TF, Mutus B. The use of glycated calmodulin from the platelet as an index of glycemic control. Clin Chem. 39:1993;815-819.
62. Kowluru RA, Heidorn DB, Edmondson SP, et al. Glycation of calmodulin chemistry and structural and functional consequences . Biochemistry. 28:1989;2220-2228.
63. Amado JA, Salas E, Botana MA, Poveda JJ, Berrazueta JR. Low levels of intraplatelet cGMP in IDDM. Diabetes Care. 16:1993;809-811.
64. Mazzanti L, Staffolani R, Martarelli D, et al. Evidence for lower nitric oxide activity in the platelets of diabetic subjects. Atti Congreesso Naz Soc It Biochim 1996.
65. Mehta JL, Chen LY, Kone BC, Mehta P, Turner P. Identification of constitutive and inducible forms of nitric oxide synthase in human platelets. J Lab Clin Med. 125:1995;370-377.
66. Ostermann H, Van de Loo J. Factors of the hemostatic system in diabetic patients a survey of controlled studies . Haemostasis. 16:1986;386-416.
67. Ardlic NG, Garrett JJ, Bell LK. Collagen increases cytoplasmatic free calcium in human plateletes. Thromb Res. 42:1986;115-124.
68. Hallama TJ, Rink TJ. Responses to adenosine diphosphate in human platelets loaded with the fluorescent calcium indicator Quin 2. J Physiol (Lond). 368:1985;131-146.
69. 2+ stores studies with Fura 2 . Biochem Biophys Res Commun. 139:1986;308-317.
70. Bergh CH, Hjalmarson A, Holm G, Anguald E, Jacobsson B. Studies on calcium exchange in platelets in human diabetes. Eur J Clin Invest. 18:1988;92-97.
71. + transport in diabetes mellitus. Diabetes. 39:1990;850-854.
72. Mazzanti L, Staffolani R, Rabini Rosa A, et al. Modifications in platelet membrane transport functions in insulin-dependent diabetes mellitus and in gestational diabetes. Biochim Biophys Acta. 1139:1992;65-69.
73. Rabini Rosa A, Fumelli P, Galassi R, et al. Increased susceptibility to lipid oxidation of LDL and erythrocyte membranes from diabetic patients. Metabolism. 43:(12):1994;1-6.